76 results match your criteria Botulinum Toxin BOTOX R Dystonia Treatment


Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study.

J Neurol Sci 2019 Apr 10;399:44-50. Epub 2019 Feb 10.

Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is an effective treatment for cervical dystonia (CD) with a well-established safety profile. In this prospective, multicentre, non-interventional study (NCT01840462) the primary objective was effectiveness (Tsui score) of aboBoNT-A in botulinum neurotoxin type A (BoNT-A) treatment-naïve and previously-treated (>2 yrs) patients after two injection cycles (at visit 3). Secondary objectives included the effectiveness of aboBoNT-A overall visits and quality of life (CDQ-24) in different CD subtypes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022510X193007
Publisher Site
http://dx.doi.org/10.1016/j.jns.2019.02.017DOI Listing
April 2019
10 Reads

High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Neurology 2019 01 21;92(1):e48-e54. Epub 2018 Nov 21.

From the Department of Neurology (P.A., A.J., J.-I.L., M.M., M.R., O.A., H.-P.H., H.H.), Medical Faculty, Heinrich Heine University Düsseldorf; and Toxogen GmbH (D.R., H.B.), Hannover, Germany.

Objective: To investigate the prevalence of neutralizing antibodies (NAbs) against botulinum neurotoxin type A (BoNT/A) during long-term BoNT/A treatment in different neurologic indications.

Methods: In this monocentric, observational cross-sectional study, 596 outpatients treated with BoNT/A for different indications were tested for BoNT/A binding antibodies by ELISA. Positive samples were investigated for NAbs with the mouse hemidiaphragm test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006688DOI Listing
January 2019
4 Reads

OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.

Toxicon 2018 Dec 10;155:38-42. Epub 2018 Oct 10.

Department of Aging, Neuroscience, Orthopedics and Head and Neck Sciences, UOC of Otorhinolaryngology, Istituto di Otorinolaringoiatria "Fondazione Policlinico Univeristario A. Gemelli IRCCS, Roma - Università Cattolica del Sacro Cuore", Italy.

Objective: To report the results of functional outcome, dose trend and relationship between onabotulinumtoxinA (onabotA) dosage and the severity of disease or time between therapy sessions in patients affected by adductor spasmodic dysphonia (ADSD).

Patients And Methods: Thirty-two patients underwent 193 EMG-guided intracordal injections of a starting dose of 2 MU of onabotA. At enrollment, each subject was administered the VHI. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00410101183039
Publisher Site
http://dx.doi.org/10.1016/j.toxicon.2018.10.006DOI Listing
December 2018
4 Reads

Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.

Eye (Lond) 2019 03 10;33(3):349-352. Epub 2018 Sep 10.

Corneo Plastic Unit, Queen Victoria Hospital NHS Trust, East Grinstead, UK.

Purpose: The purpose of this study was to assess the long-term outcome of onabotulinum used to treat facial dystonia and compare a flexible and fixed treatment regimen.

Methods: This was a retrospective comparative study looking at benign essential blepharospasm (BEB), hemifacial spasm (HFS) and aberrant facial nerve regeneration synkinesis (AFR) treatment with onabotulinum toxin A (Botox®) over a minimum of 10 years. Fifty-one patients were recruited into the study, with each dystonia subgroup having 17 patients. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41433-018-0203-3
Publisher Site
http://dx.doi.org/10.1038/s41433-018-0203-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460690PMC
March 2019
41 Reads

Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport ).

Eur J Neurol 2019 06 30;26(6):943-e65. Epub 2018 Sep 30.

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Background And Purpose: In patients with cervical dystonia, abobotulinumtoxinA solution for injection (ASI) has been shown to be similarly effective to freeze-dried abobotulinumtoxinA in reducing Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores. In this secondary analysis, quality of life data as evaluated with the Cervical Dystonia Impact Profile (CDIP-58) are presented.

Methods: This was a double-blind, randomized, active and placebo-controlled study followed by an open-label extension (NCT01261611). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13800DOI Listing
June 2019
8 Reads

Iatrogenic Botulism Outbreak in Egypt due to a Counterfeit Botulinum Toxin A Preparation - A Descriptive Series of Patient Features and Outcome.

Basic Clin Pharmacol Toxicol 2018 Nov 21;123(5):622-627. Epub 2018 Jun 21.

Department of Medical and Toxicological Critical Care, Lariboisière Hospital, INSERM UMRS-1144, Paris-Diderot University, Paris, France.

Iatrogenic botulism resulting from the substantial increase in use of botulinum neurotoxin type A (BoNT-A) treatment is rarely reported. We aimed to describe a large iatrogenic botulism outbreak in Egypt in June-July 2017. Nine patients developed botulism after receiving intramuscular injections of BoNT-A (dose: 200-300 IU) to treat cerebral palsy (N = 7), spastic dystonia (N = 1) and hyperhidrosis (N = 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcpt.13048DOI Listing
November 2018
45 Reads

Evidence on botulinum toxin in selected disorders.

Toxicon 2018 Jun 3;147:134-140. Epub 2018 Feb 3.

Department of Neuromuscular Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria Clostridium botulinum that has become widely used for various neurologic indications. The four toxin formulations currently available for use in the United States (approved by the Food and Drug Administration) are onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and rimabotulinumtoxinB (Myobloc). While the FDA-approved labels indicate that potency conversions should not be done, literature supports relative dose equivalents of approximately 1:1:2-4:50-100, respectively. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00410101183003
Publisher Site
http://dx.doi.org/10.1016/j.toxicon.2018.01.019DOI Listing
June 2018
71 Reads

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.

Int J Neurosci 2018 Jul 17;128(7):619-626. Epub 2018 Jan 17.

h Methodist Neurological Institute , Houston , TX , USA.

Purpose/aim: AbobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ, USA) is an acetylcholine release inhibitor and a neuromuscular blocking agent. The United States prescribing information for abobotulinumtoxinA previously indicated only one dilution for cervical dystonia: 500 U/1 mL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2017.1406935DOI Listing
July 2018
10 Reads

The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.

Immunol Invest 2018 Jan 11;47(1):18-39. Epub 2017 Sep 11.

a Department of Biochemistry and Molecular Biology.

We have recently mapped the in vitro proliferative responses of T cells from botulinum neurotoxin type A (BoNT/A)-treated cervical dystonia (CD) patients with overlapping peptides encompassing BoNT/A heavy chain (residues 449-1296). In the present study, we determined the recognition profiles, by peripheral blood lymphocytes (PBL) from the same set of patients, of BoNT/A light (L) chain (residues 1-453) by using 32 synthetic overlapping peptides that encompassed the entire L chain. Profiles of the T-cell responses (expressed in stimulation index, SI; Z score based on transformed SI) to the peptides varied among the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08820139.2017.1368544DOI Listing
January 2018
16 Reads

Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment.

Toxins (Basel) 2017 08 23;9(9). Epub 2017 Aug 23.

Department of Neurology and Clinical Neurophysiology, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands.

Botulinum toxin (BoNT) injections in the dystonic muscles is the preferred treatment for Cervical Dystonia (CD), but the proper identification of the dystonic muscles remains a challenge. Previous studies showed decreased 8-14 Hz autospectral power in the electromyography (EMG) of splenius muscles in CD patients. Cumulative distribution functions (CDF's) of dystonic muscles showed increased CDF values, representing increased autospectral powers between 3 and 10 Hz, relative to power between 3 and 32 Hz. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins9090256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618189PMC
August 2017
34 Reads

Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.

Funct Neurol 2017 Apr/Jun;32(2):103-110

Botulinum toxin is a well-established treatment for a number of conditions involving muscle hyperactivity, such as focal dystonia and spastic paresis. However, current injection practice is not standardized and there is a clear need for structured training. An international group of experts in the management of patients with cervical dystonia (CD) and spastic paresis created a steering committee (SC). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507152PMC
http://dx.doi.org/10.11138/fneur/2017.32.2.103DOI Listing
January 2018
13 Reads

Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.

J Neuroimmunol 2017 05 21;306:31-39. Epub 2017 Feb 21.

Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:

We have conducted a 26-month-long comparative study involving young patients (2-6years old) with a clinical diagnosis of spastic equinus secondary to cerebral palsy who have been treated with BoNT/A (BOTOX®, Allergan) tri-annually or annually. Serum samples were obtained to determine the presence or absence of blocking antibodies (Abs) by a mouse protection assay (MPA) and levels of anti-BoNT/A Abs by radioimmune assay (RIA). HLA DQ alleles were typed using blood samples to determine the possible association of certain HLA type(s) with the disease or with the Ab status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2017.02.014DOI Listing
May 2017
13 Reads

OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach.

PM R 2017 Oct 7;9(10):960-968. Epub 2017 Mar 7.

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY(§§).

Background: OnabotulinumtoxinA is approved for the treatment of upper and lower limb spasticity in adults. Guidance on common postures and onabotulinumtoxinA injection paradigms for upper limb spasticity has been developed via a Delphi Panel; however, similar guidance for lower limb spasticity has not been established.

Objective: To define a clinically recommended treatment paradigm for the use of onabotulinumtoxinA for each common posture among patients with poststroke lower limb spasticity (PSLLS) and to identify the most common PSLLS aggregate postures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pmrj.2017.02.014DOI Listing
October 2017
18 Reads

Safety of botulinum toxin short interval therapy using incobotulinumtoxin A.

J Neural Transm (Vienna) 2017 04 17;124(4):437-440. Epub 2016 Oct 17.

Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

The therapeutic efficacy of botulinum toxin (BT) can be completely blocked by formation of BT antibodies (BTAB), thus producing antibody-induced therapy failure (ABTF). One of the risk factors for this is the interval between two subsequent injection series. To prevent BTAB formation it is universally recommended not to use interinjection intervals of less than 12 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-016-1628-0DOI Listing
April 2017
2 Reads

Predicting Improvement in Writer's Cramp Symptoms following Botulinum Neurotoxin Injection Therapy.

Tremor Other Hyperkinet Mov (N Y) 2016 3;6:410. Epub 2016 Sep 3.

Lawson Health Research Institute, London, ON, Canada; Department of Clinical Neurological Sciences, Western University, London, ON, Canada.

Introduction: Writer's cramp is a specific focal hand dystonia causing abnormal posturing and tremor in the upper limb. The most popular medical intervention, botulinum neurotoxin type A (BoNT-A) therapy, is variably effective for 50-70% of patients. BoNT-A non-responders undergo ineffective treatment and may experience significant side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/D82Z15Q5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013165PMC
September 2016
18 Reads

Use of Alleviating Maneuvers for Periocular Facial Dystonias.

JAMA Ophthalmol 2016 Nov;134(11):1247-1252

Adnexal Department, Moorfields Eye Hospital, London, England.

Importance: Patients with benign essential blepharospasm or hemifacial spasm are known to use botulinum toxin injections and alleviating maneuvers to help control their symptoms. The clinical correlates between the use of botulinum toxin injections and the use of alleviating maneuvers are not well established.

Objective: To determine whether the use of alleviating maneuvers for benign essential blepharospasm or hemifacial spasm correlates with disease severity or botulinum toxin treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2016.3277DOI Listing
November 2016
37 Reads

Botulinum toxin injection in laryngeal dyspnea.

Eur Arch Otorhinolaryngol 2017 Feb 6;274(2):909-917. Epub 2016 Sep 6.

Neurosciences Department, Toulouse University Hospital, Toulouse Neuroimaging Center, University of Toulouse, Inserm UPS, Toulouse, France.

Data, regarding the use of botulinum toxin (BT-A) in laryngeal dyspnea, are scarce, coming from some cases reports in the literature, including Vocal fold paralysis, laryngeal dystonia, vocal cord dysfunction also called paradoxical motion of the vocal fold (PMVF), and post-neuroleptic laryngeal dyskinesia. There is no consensus regarding the muscles and the doses to inject. The aim of this study is to present a retrospective review of patients treated in our ENT Department by BT-A injection in this indication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00405-016-4289-6DOI Listing
February 2017
33 Reads

IncobotulinumtoxinA: A Review in Upper Limb Spasticity.

Drugs 2016 Sep;76(14):1373-9

Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.

Intramuscular incobotulinumtoxinA (Xeomin(®)) is indicated for the treatment or improvement of adult patients with upper limb spasticity (featured indication), cervical dystonia, blepharospasm and glabellar lines. It is a highly purified formulation of botulinum toxin type A that inhibits acetylcholine signalling at neuromuscular junctions, reducing muscle hypertonia. This narrative review discusses the clinical use of incobotulinumtoxinA in adults with upper limb spasticity and summarizes its pharmacological properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0630-zDOI Listing
September 2016
21 Reads

Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia.

Value Health 2016 Mar-Apr;19(2):145-52. Epub 2015 Dec 29.

Thema Consulting Pty Ltd., Pyrmont, New South Wales, Australia. Electronic address:

Background: Incobotulinumtoxin-A (Xeomin(®), Merz Pharmaceuticals, Sydney, New South Wales) is a formulation of botulinum neurotoxin type A that is free of complexing proteins.

Objective: To assess the cost-effectiveness of incobotulinumtoxin-A administered with flexible treatment intervals compared to onabotulinumtoxin-A (Botox(®), Sydney, New South Wales) in blepharospasm and cervical dystonia from the perspective of Australian health care providers.

Methods: A Markov state transition model was developed to perform a cost-utility analysis to compare the cost and health benefits of incobotulinumtoxin-A to that of onabotulinumtoxin-A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jval.2015.11.009DOI Listing
August 2016
54 Reads

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.

Toxins (Basel) 2016 Mar 4;8(3). Epub 2016 Mar 4.

Department of Oncology and Onco-Hematology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.

Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three leading botulinum neurotoxin type A products available in the Western Hemisphere: onabotulinum toxin-A (ONA) Botox(®), abobotulinum toxin-A (ABO), Dysport(®), and incobotulinum toxin A (INCO, Xeomin(®)). Although the efficacies are similar, there is an intense debate regarding the comparability of various preparations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/toxins8030065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810210PMC
March 2016
18 Reads

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.

J Neurol 2016 Apr 25;263(4):772-80. Epub 2016 Feb 25.

School of Medicine, Johns Hopkins University, 600 N. Wolfe Street, Meyer 6-181B, Baltimore, MD, 21287, USA.

A systematic pair-wise comparison of all available botulinum toxin serotype A and B treatments for cervical dystonia (CD) was conducted, as direct head-to-head clinical trial comparisons are lacking. Five botulinum toxin products: Dysport(®) (abobotulinumtoxinA), Botox(®) (onabotulinumtoxinA), Xeomin(®) (incobotulinumtoxinA), Prosigne(®) (Chinese botulinum toxin serotype A) and Myobloc(®) (rimabotulinumtoxinB) have demonstrated efficacy for managing CD. A pair-wise efficacy and safety comparison was performed for all toxins based on literature-reported clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-016-8050-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826665PMC
April 2016
36 Reads

Botulinum toxin B increases intrinsic muscle activity in organotypic spinal cord-skeletal muscle co-cultures.

Toxicol Lett 2016 Feb 7;244:167-171. Epub 2015 Aug 7.

Experimental Anesthesiology Section, Department of Anesthesiology and Intensive Care Medicine, Eberhard-Karls-University, Tübingen, Germany.

In organotypic spinal cord-skeletal muscle co-cultures, motoneurons are driven by locomotor commands and induce contractions in surrounding muscle fibres. Using these co-cultures, it has been shown that effects of organophosphorus compounds on neuromuscular synapses can be determined in vitro. In the present study we aimed to extend this in vitro tool for pharmacologic testing of botulinum toxin B. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2015.08.003DOI Listing
February 2016
57 Reads

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.

Drug Des Devel Ther 2015 1;9:1913-26. Epub 2015 Apr 1.

Rush University Medical Center, Chicago, IL, USA.

Background: IncobotulinumtoxinA (Xeomin(®)) is a purified botulinum neurotoxin type A formulation, free from complexing proteins, with proven efficacy and good tolerability for the treatment of neurological conditions such as blepharospasm, cervical dystonia (CD), and post-stroke spasticity of the upper limb. This article provides a comprehensive overview of incobotulinumtoxinA based on randomized controlled trials and prospective clinical studies.

Summary: IncobotulinumtoxinA provides clinical efficacy in treating blepharospasm, CD, and upper-limb post-stroke spasticity based on randomized, double-blind, placebo-controlled trials with open-label extension periods (total study duration up to 89 weeks). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S79193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389813PMC
September 2016
16 Reads

Botulinum toxin therapy for cervical dystonia: the science of dosing.

Tremor Other Hyperkinet Mov (N Y) 2014 12;4:273. Epub 2014 Nov 12.

Merz North America, Inc., Greensboro, NC, USA.

The first-line treatment for cervical dystonia (CD) is botulinum toxin type A (BoNT-A), which has been established as a highly effective and well-tolerated therapy. However, this treatment is also complex and challenging to apply in clinical practice. Approximately 20% of patients discontinue therapy due to treatment failure, adverse effects, and other reasons. Read More

View Article

Download full-text PDF

Source
http://www.tremorjournal.org/index.php/tremor/article/view/2
Publisher Site
http://dx.doi.org/10.7916/D84X56BFDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233211PMC
November 2014
26 Reads

Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.

J Rehabil Med 2015 Feb;47(2):183-6

Institute of Neurological Sciences, Southern General Hospital, G51 4TF Glasgow, United Kingdom.

Objective: To explore the dose equivalence ratio and treatment costs for abobotulinumtoxinA and incobotulinumtoxinA for patients with focal dystonias.

Design: Patient chart review.

Subjects/patients: Adult patients with blepharospasm (n = 19), cervical dystonia (n = 122), hemifacial spasm (n = 91) or segmental/generalized dystonia (n = 19) at a neurology outpatient clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/16501977-1895DOI Listing
February 2015
27 Reads

IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.

J Neurol Sci 2014 Nov 10;346(1-2):116-20. Epub 2014 Aug 10.

Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt, Germany.

Typically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) are administered at approximately 3-month intervals, reflecting concerns that shorter intervals might increase the risk of adverse events (AEs) and development of neutralizing antibodies. These post-hoc analyses investigated flexible incobotulinumtoxinA (Xeomin®) injection intervals (6-20 weeks) in patients with blepharospasm or CD. Patients received up to 6 injections at intervals ≥ 6 weeks, as determined by physician assessment upon patient request. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022510X140051
Publisher Site
http://dx.doi.org/10.1016/j.jns.2014.08.004DOI Listing
November 2014
6 Reads

Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data.

J Med Econ 2014 Nov 29;17(11):803-9. Epub 2014 Aug 29.

Evidera, Health Economics and Epidemiology , Metro Building, 6th Floor, 1 Butterwick, London W6 8DL , UK.

Purpose: This study aimed to explore the burden of illness associated with cervical dystonia (CD), including possible demographic and humanistic correlates of baseline disease severity.

Methods: The analysis involved the five multinational randomized, placebo-controlled clinical trials that had evaluated the efficacy and safety of Dysport® in patients with CD, including assessment using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Patient-level TWSTRS scores from the individual studies were meta-analysed to estimate disease severity at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3111/13696998.2014.953680DOI Listing
November 2014
21 Reads

Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects.

J Neural Transm (Vienna) 2015 Feb 23;122(2):297-300. Epub 2014 Jul 23.

Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany,

We sought to explore the therapeutic effect of botulinum toxin (BT) therapy by analysing the time between the BT application and the onset of its decrease (treatment duration, TD), the inter-injection interval (II), and the excess time (ET, ET = II-TD). For this we studied 59 patients (37 females, 22 males, age 52.6 ± 10. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00702-014-1253
Web Search
http://link.springer.com/10.1007/s00702-014-1253-8
Publisher Site
http://dx.doi.org/10.1007/s00702-014-1253-8DOI Listing
February 2015
37 Reads

Safety aspects of incobotulinumtoxinA high-dose therapy.

J Neural Transm (Vienna) 2015 Feb 17;122(2):327-33. Epub 2014 Jul 17.

Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany,

Botulinum toxin (BT) used for dystonia and spasticity is dosed according to the number of target muscles and the severity of their muscle hyperactivities. With this no other drug is used in a broader dose range than BT. The upper end of this range, however, still needs to be explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-014-1252-9DOI Listing
February 2015
21 Reads

Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.

J Voice 2014 Sep 18;28(5):614-7. Epub 2014 Jun 18.

Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina. Electronic address:

Objective: Chemical denervation with botulinum toxin A is the current standard of treatment for spasmodic dysphonia, but dosage is determined individually after a titration period that can take months to years. The objective of this study was to determine if age, body mass index (BMI), overall health, and socioeconomic factors were associated with a patient's optimal dose of botulinum toxin.

Study Design And Methods: This retrospective chart review looked at 32 patients with stabilized doses of botulinum toxin. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08921997140005
Publisher Site
http://dx.doi.org/10.1016/j.jvoice.2013.10.024DOI Listing
September 2014
33 Reads

[Cost analysis of the use of botulinum toxin type A in Spain].

Farm Hosp 2014 May 1;38(3):193-201. Epub 2014 May 1.

Pharmacoeconomics & Outcomes Research Iberia, Madrid.

Objective: To estimate treatment costs of blepharospasm, cervical dystonia(CD), upper limb spasticity (ULS) and spasticity in children with cerebral palsy (SCCP) with botulinum neurotoxin type A (BoNT-A) in Spain.

Method: Annual BoNT-A treatment costs were calculated (2013 ex-factory price () applying RDL 8/2010 and RDL 9/2011 deductions), based on initial dose (id), average dose (ad) and maximum dose (md) according to Summary of Product Characteristics of Botox® (100U/50U), Dysport®(500U) and Xeomin® (100U) and considering the use of complete vials.In addition, annual treatment costs were calculated considering the useof vials in more than one patient and also patient population annual treatment costs based on diseases' prevalence. Read More

View Article

Download full-text PDF

Source
http://www.aulamedica.es/fh/pdf/1163.pdf
Publisher Site
http://dx.doi.org/10.7399/fh.2014.38.3.1163DOI Listing
May 2014
15 Reads

IncobotulinumtoxinA (Xeomin(®)) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport(®)).

J Neural Transm (Vienna) 2014 Jul 18;121(7):769-71. Epub 2014 Mar 18.

Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany,

IncobotulinumtoxinA has not produced a single case of antibody-induced therapy failure after 8 years of worldwide usage. We are reporting a patient with progressive hereditary juvenile onset generalised dystonia who was pretreated with abobotulinumtoxinA for 15 years, before she received incobotulinumtoxinA. To the fifth and sixth applications, she responded with complete therapy failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-014-1165-7DOI Listing
July 2014
3 Reads

Diagnosis and treatment of abductor hallucis focal dystonia with botulinum toxin injection: a case presentation.

PM R 2013 Aug;5(8):726-8

Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pmrj.2013.04.003DOI Listing
August 2013
9 Reads

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).

J Neural Transm (Vienna) 2014 Jan 4;121(1):29-31. Epub 2013 Aug 4.

Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany,

Several botulinum toxin (BT) drugs are licensed for the treatment of cervical dystonia (CD). We wanted to compare the efficacy and the potency labelling of incobotulinumtoxinA (Xeomin(®)) and onabotulinumtoxinA (Botox(®)) by analysing the duration of their therapeutic effect in a cross-over study. For this we studied 40 CD patients (26 females, 14 males, age at therapy onset 52. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00702-013-1076-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889804PMC
January 2014
36 Reads

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.

J Neural Transm (Vienna) 2013 Dec 19;120(12):1699-707. Epub 2013 Jun 19.

Movement Disorders Center of Arizona, 9590 E. Ironwood Square Drive, #225, Scottsdale, AZ, 85258, USA,

IncobotulinumtoxinA (Xeomin(®), NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and safety to onabotulinumtoxinA in treating cervical dystonia (CD). This study evaluated the efficacy and safety of repeated incobotulinumtoxinA injections in subjects with CD. Following a ≤20-week placebo-controlled, randomized, double-blind, single-dose main period, subjects could enter a ≤68-week prospective, randomized, double-blind, repeated-dose, flexible-interval (minimum 6 weeks) extension period with 240 U or 120 U of incobotulinumtoxinA (≤5 injections). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00702-013-1048
Web Search
http://link.springer.com/10.1007/s00702-013-1048-3
Publisher Site
http://dx.doi.org/10.1007/s00702-013-1048-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834167PMC
December 2013
11 Reads

The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.

Toxicon 2013 Sep 23;71:18-24. Epub 2013 May 23.

Allergan, Inc., LLC, 2525 Dupont Drive, Irvine, CA 92612-1599, USA.

Botulinum neurotoxins (BoNT) are approved for a number of therapeutic indications, including blepharospasm, cervical dystonia and hyperhidrosis, and have also shown efficacy in a variety of pain disorders. The potency of any given BoNT preparation can be routinely assessed by using the Digit Abduction Score (DAS) assay, which measures the local muscle weakening efficacy of BoNT following injection into mouse hindlimb muscle. While most studies have employed mice to assess BoNT efficacy in the DAS, few have utilized rats. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00410101130018
Publisher Site
http://dx.doi.org/10.1016/j.toxicon.2013.05.004DOI Listing
September 2013
84 Reads

A double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.

PLoS One 2013 28;8(2):e56479. Epub 2013 Feb 28.

Physical Medicine and Rehabilitation Service, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil.

Background: Botulinum toxin type A (btxA) is one of the main treatment choices for patients with spasticity. Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia. However, there are no randomized clinical trials comparing these formulations in spasticity treatment. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0056479PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585303PMC
August 2013
33 Reads

[A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia].

Brain Nerve 2013 Feb;65(2):203-11

Department of Clinical Neuroscience, Tokushima University Graduate School, Japan.

We conducted a single-dose, placebo-controlled, double-blind, dose-response study of NerBloc®(rimabotulinumtoxinB) in patients with cervical dystonia (placebo, 2,500 U, 5,000 U, 10,000 U). The primary endpoint, the change in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-total score at 4 weeks post dose from baseline, showed a significant improvement in all treatment groups (2,500 U, 5,000 U, 10,000 U) compared with the placebo group. As for the secondary endpoints, the change of TWSTRS subscales, severity, disability and pain scores, at 4 weeks post dose in 10,000 U group, showed a significant improvement compared with the placebo group, however, no significant differences were observed between 2,500 U or 5,000 U and placebo group. Read More

View Article

Download full-text PDF

Source
February 2013
6 Reads

Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.

Clin Neuropharmacol 2012 Sep-Oct;35(5):215-23

US WorldMeds, LLC, Louisville, KY 40207, USA.

Objective: Therapeutic botulinum toxins are antigenic proteins with the potential to produce antibodies (Abs). It is, however, unclear whether Abs to Myobloc® (rimabotulinumtoxinB, botulinum toxin type B, BoNT-B) impact the efficacy and safety of BoNT-B treatment of cervical dystonia (CD). The objective was to determine if Abs to BoNT-B impact the efficacy or safety of long-term BoNT-B treatment of CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0b013e318263163cDOI Listing
July 2013
5 Reads

Severe nervous system complications after botulinum type A therapy: three case reports with reviews of FDA-reported nervous system adverse effects.

PM R 2012 Aug;4(8):613-23

Neurology Department, Virginia Commonwealth University, MCV Campus ACC5, 417 N 11th St., Richmond, VA 23298-0599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pmrj.2012.04.016DOI Listing
August 2012
8 Reads

Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.

Headache 2012 Sep 18;52(8):1219-25. Epub 2012 May 18.

Palm Beach Headache Center, West Palm Beach, FL 33407, USA.

Objective: The objective of this study was to assess the clinical benefits of onabotulinumtoxinA (BOTOX®) treatment on the symptoms of cervical dystonia and the frequency, severity, and associated symptoms of migraine in patients with cervical dystonia and concurrent migraine.

Background: Botulinum toxin is established as first-line treatment of cervical dystonia. Recent clinical trials have shown onabotulinumtoxinA to be an effective prophylactic therapy for patients with chronic migraine, and onabotulinumtoxinA has been approved for use in this patient population by the Food and Drug Administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1526-4610.2012.02164.xDOI Listing
September 2012
14 Reads

A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.

Parkinsonism Relat Disord 2012 Jun 9;18(5):441-5. Epub 2012 Mar 9.

Georgetown University Hospital, GUH 7PHC, 3800 Reservoir Road, NW, Washington, DC 20007, USA.

Xeomin(®) (incobotulinumtoxinA; Merz Pharmaceuticals, Frankfurt am Main, Germany) was first introduced in Germany for movement disorders in 2005. In 2010, it was approved for use in the United States by the FDA for the treatment of cervical dystonia (CD) and blepharospasm. It is a unique botulinum type A formulation free of any complexing proteins and contains only the pure 150 kD neurotoxin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2012.02.008DOI Listing
June 2012
13 Reads

Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital.

Arq Neuropsiquiatr 2011 Dec;69(6):900-4

Movement Disorders Clinic of the Division of Neurology, Hospital das Clínicas, University of São Paulo, School of Medicine, Brazil.

Objective: The purpose of this study was to evaluate quality of life (QoL) in a Brazilian population of individuals with cervical dystonia (CD) without effect of botulinum toxin (BTx) or with only residual effect of BTx, and identify possible physical and social aspects that affect their QoL.

Method: Sixty five out of sixty seven consecutive patients with CD were assessed with two instruments: Short-form Health Survey with 36 questions (SF-36) and Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS).

Results: Severity of CD (TWSTRS) correlated moderately with two SF-36 subscale: role-physical (r= -0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0004-282x2011000700010DOI Listing
December 2011
3 Reads
5 Citations
1.010 Impact Factor

A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.

Neuropsychiatr Dis Treat 2012 23;8:13-25. Epub 2011 Dec 23.

Department of Neurology, Baylor College of Medicine, Houston, TX, USA.

Dystonia is a movement disorder of uncertain pathogenesis that is characterized by involuntary and inappropriate muscle contractions which cause sustained abnormal postures and movements of multiple or single (focal) body regions. The most common focal dystonias are cervical dystonia (CD) and blepharospasm (BSP). The first-line recommended treatment for CD and BSP is injection with botulinum toxin (BoNT), of which two serotypes are available: BoNT type A (BoNT/A) and BoNT type B (BoNT/B). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/NDT.S16085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261649PMC
August 2012
8 Reads

Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).

BMC Neurol 2011 Nov 4;11:140. Epub 2011 Nov 4.

Baylor College of Medicine, Department of Neurology, Houston, TX, USA.

Background: A registry of patients with cervical dystonia (Cervical Dystonia Patient Registry for Observation of onaBotulinumtoxinA Efficacy [CD PROBE]) was initiated to capture data regarding physician practices and patient outcomes with onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA, USA). Methods and baseline demographics from an interim analysis are provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2377-11-140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220636PMC
November 2011
23 Reads

Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.

Authors:
D Dressler

Eur J Neurol 2012 Mar 28;19(3):385-9. Epub 2011 Oct 28.

Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany.

In 2005, incobotulinumtoxinA (Xeomin(®) ), a new botulinum toxin (BT) type A drug without complexing proteins (CPs), became available. This paper reviews the specific features of Xeomin(®) and the experience gathered with it during the last 5 years. Compared with conventional BT drugs, Xeomin(®) 's extended shelf live and its simplified temperature restrictions indicate that CPs are not necessary for BT drug stability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1468-1331.2011.03559.xDOI Listing
March 2012
15 Reads

Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.

J Neurol Sci 2011 Sep 18;308(1-2):103-9. Epub 2011 Jul 18.

Merz Pharmaceuticals GmbH, Frankfurt, Germany.

Objective: IncobotulinumtoxinA differs from available formulations in that it does not have accessory proteins. IncobotulinumtoxinA has previously shown non-inferiority to onabotulinumtoxinA for the treatment of CD with a 1:1 dosing regimen. The objective of this study was to compare the safety and efficacy of incobotulinumtoxinA (120 U, 240 U; Merz Pharmaceuticals) to placebo in subjects with cervical dystonia (CD). Read More

View Article

Download full-text PDF

Source
http://jnnp.bmj.com/content/84/9/1014.full.pdf
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S0022510X1100303
Publisher Site
http://dx.doi.org/10.1016/j.jns.2011.05.041DOI Listing
September 2011
8 Reads

[Clinical application of botulinum toxin].

Authors:
Takahiro Mezaki

Brain Nerve 2011 Jul;63(7):785-94

Department of Neurology, Sakakibara Hakuho Hospital, Mie, Japan.

The clinical application of botulinum toxin (BoNT) was first proposed by Justinus Kerner in 1822. BoNT was formally accepted as a therapeutic agent in the 1970s, and currently, it is used worldwide for treating diseases as well as for cosmetic conditions. In Japan, Botox® is the only type A formulation that has been officially approved for the treatment of blepharospasm, hemifacial spasm, cervical dystonia, pes equinus of cerebral palsy, adult spasticity of upper and lower limbs, and Botox Vista® is applied for glabellar frown lines. Read More

View Article

Download full-text PDF

Source
July 2011
20 Reads